SCHEDULE: Armistice Capital Discloses 7.88% Stake in MacroGenics

Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 7.88% of MacroGenics, Inc. common stock as of June 30, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating they collectively beneficially own 5,006,752 shares of MacroGenics, Inc. common stock.
• This ownership stake represents 7.88% of the class of securities.
• The filing is an amendment (Amendment No. 8) and the event date requiring the filing is June 30, 2026.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the disclosure of a significant ownership stake by an investment manager, which could signal potential activist intentions or a belief that the stock is undervalued, but without explicit positive or negative operational news.

Positives

• A significant investment firm has taken a notable stake in the company, which could be interpreted as a sign of confidence in the company's long-term prospects by the investor.
• The filing clearly delineates the ownership structure and reporting responsibilities between Armistice Capital, LLC, Steven Boyd, and the Master Fund.

Negatives

• The filing does not contain any operational or financial performance data for MacroGenics, Inc., making it difficult to assess the company's current health.
• The nature of the investment (e.g., long-term, activist) is not specified, leaving room for speculation.

Risks

• Potential for increased shareholder activism or pressure on management from Armistice Capital, LLC.
• The filing does not provide insights into MacroGenics' operational performance or future prospects, leaving investors to rely on other sources for company health assessment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding MacroGenics, Inc.'s future performance. It solely reports on ownership stakes.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant ownership filings like this Schedule 13G often precede or coincide with shifts in investor sentiment or potential strategic actions by the reporting entity. In the biotechnology sector, where MacroGenics operates, such disclosures can be particularly impactful given the often volatile nature of drug development and market approvals.

Stakeholder Impact

• Shareholders: May interpret the increased stake as a positive signal or a precursor to activist involvement, potentially influencing trading activity.
• Management: May face increased scrutiny or pressure from a significant new stakeholder.
• Employees: Indirect impact through potential strategic shifts or governance changes driven by the new major shareholder.

Next Steps

• Monitor future filings from Armistice Capital, LLC and Steven Boyd for any changes in their ownership stake.
• Observe any public statements or actions by Armistice Capital, LLC regarding MacroGenics, Inc.

Key Dates

Recommendation

The filing indicates a significant ownership stake by Armistice Capital, which could signal a belief in undervaluation or potential for change. However, without any operational or financial updates from MacroGenics, it's prudent to hold and await further information or actions from the new major shareholder before making a definitive buy or sell decision.

Keywords

MacroGenics, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Investment Management, Common Stock, Ownership Stake